Filing Flows › Comparisons › ROIV vs BCYC
Roivant Sciences vs Bicycle Therapeutics: ROIV and BCYC compared
Roivant Sciences is the larger company: $35.1M of revenue in its latest quarter (Q2 FY27) against $34.1M for Bicycle Therapeutics (Q3 2026). Roivant Sciences is growing faster (22× against +190% a year earlier). Bicycle Therapeutics is more profitable, with an operating margin of -39.6% against -763.2%.
Where the money goes: ROIV and BCYC
Roivant Sciences (ROIV) · Q2 FY27
Roivant Sciences, Q2 FY27: revenue $35.1M (22× year over year), operating margin -763.2%, net loss $137M, operating cash flow $594M. The chart follows the revenue to costs, profit and cash.
Bicycle Therapeutics (BCYC) · Q3 2026
Bicycle Therapeutics, Q3 2026: revenue $34.1M (+190% year over year), operating margin -39.6%, net loss $10.5M, operating cash flow −$40.3M. The chart follows the revenue to costs, profit and cash.
| Roivant Sciences (ROIV) | Bicycle Therapeutics (BCYC) | |
|---|---|---|
| Latest quarter | Q2 FY27 | Q3 2026 |
| Revenue | $35.1M | $34.1M |
| Revenue growth, Y/Y | 22× | +190% |
| Operating margin | -763.2% | -39.6% |
| Net earnings | −$137M | −$10.5M |
| Net margin | -390.7% | -30.8% |
| Operating cash flow | $594M | −$40.3M |
| Free cash flow | $594M | — |
Where the revenue comes from
Roivant Sciences
- Product revenue, net: $31.0M (88%)
- License, milestone and other revenue: $4.2M (12%)
Questions
Which is bigger, Roivant Sciences or Bicycle Therapeutics?
Roivant Sciences is the larger company: $35.1M of revenue in its latest quarter (Q2 FY27) against $34.1M for Bicycle Therapeutics (Q3 2026).
Is Roivant Sciences or Bicycle Therapeutics growing faster?
Roivant Sciences is growing faster (22× against +190% a year earlier).
Which is more profitable, Roivant Sciences or Bicycle Therapeutics?
Bicycle Therapeutics is more profitable, with an operating margin of -39.6% against -763.2%.
More: Roivant Sciences earnings · how Roivant Sciences makes money · Bicycle Therapeutics earnings · how Bicycle Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 9, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.